Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0

作者：

Grunwald, Viktor ^{[1
,2
]}

Powles, Thomas ^{[3
,4
]}

Eto, Masatoshi ^{[5
]}

Kopyltsov, Evgeny ^{[6
]}

Rha, Sun Young ^{[7
]}

Porta, Camillo ^{[8
]}

Motzer, Robert ^{[9
]}

Hutson, Thomas E. ^{[10
]}

Mendez-Vidal, Maria Jose ^{[11
]}

Hong, Sung-Hoo ^{[12
]}

Winquist, Eric ^{[13
]}

Goh, Jeffrey C. ^{[14
,15
]}

Maroto, Pablo ^{[16
]}

Buchler, Tomas ^{[17
,18
]}

Takagi, Toshio ^{[19
]}

Burgents, Joseph E. ^{[20
]}

Perini, Rodolfo ^{[21
]}

He, Cixin ^{[22
]}

Okpara, Chinyere E. ^{[23
]}

McKenzie, Jodi ^{[24
]}

Choueiri, Toni K. ^{[25
]}

机构：

[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany

[2] Univ Hosp Essen, Clin Urol, Essen, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] Queen Mary Univ London, Royal Free Hosp, London, England

[5] Kyushu Univ, Dept Urol, Fukuoka, Japan

[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia

[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea

[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Texas Oncol, Med Oncol, Dallas, TX USA

[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain

[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea

[13] Univ Western Ontario, Dept Oncol, London, ON, Canada

[14] ICON Res, South Brisbane, Qld, Australia

[15] Univ Queensland, St Lucia, Qld, Australia

[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic

[18] Thomayer Univ Hosp, Prague, Czech Republic

[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[21] Merck & Co Inc, Clin Res, Rahway, NJ USA

[22] Eisai Inc, Biostat, Nutley, NJ USA

[23] Eisai Ltd, Clin Res, Hatfield, England

[24] Eisai Inc, Clin Res, Nutley, NJ USA

[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 13卷

关键词：

renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;

D O I：

10.3389/fonc.2023.1343027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[31] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
Lee, Chung-Han
Makker, Vicky
Rasco, Drew
Taylor, Matthew
Dutcus, Corina
Shumaker, Robert
Schmidt, Emmett
Stepan, Daniel E.
Li, Di
Young, Louise
Motzer, Robert
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
[32] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
Gruenwald, V
Hutson, T.
Choueiri, T. K.
Motzer, R.
Rha, S. Y.
Alyasova, A.
Merchan, J.
Gurney, H.
Peer, A.
Takagi, T.
Porta, C.
Powles, T.
De Giorgi, U.
Vaishampayan, U.
Schmidinger, M.
Glen, H.
Rodriguez-Lopez, K.
Xing, D.
Dutta, L.
Eto, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 275
[33] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
Haro-Silerio, Jaime Ivan
Johns, Andrew
Moussa, Mohammad Jad
Wang, Mindy
Wang, Emily
Kovitz, Craig A.
Campbell, Matthew T.
Jonasch, Eric
Shah, Amishi Yogesh
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
[34] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) plus everolimus (EVE) versus sunitinib (SUN) treatment arms.
Hutson, Thomas E.
Choueiri, Toni K.
Motzer, Robert J.
Rha, Sun Young
Alyasova, Anna
Merchan, Jaime R.
Gurney, Howard
Peer, Avivit
Takagi, Toshio
Porta, Camillo
Powles, Thomas
Grunwald, Viktor
De Giorgi, Ugo
Vaishampayan, Ulka N.
Schmidinger, Manuela
Glen, Hilary
Rodriguez-Lopez, Karla
Xing, Dongyuan
Dutta, Lea
Eto, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Cost-effectiveness and budget impact of pembrolizumab plus axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
Xander, Nicolas S. H.
Fiets, W. Edward
Uyl-de Groot, Carin A.
FRONTIERS IN ONCOLOGY, 2023, 13
[36] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
Lee, C-H.
Makker, V.
Rasco, D.
Taylor, M.
Dutcus, C.
Shumaker, R.
Schmidt, E. V.
Stepan, D.
Li, D.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2017, 28
[37] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Grunwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Merchan, Jamie R.
Goh, Jeffrey C.
De Giorgi, Ugo
Melichar, Bohuslav
Hong, Sung-Hoo
Gurney, Howard
Rodriguez-Lopez, Karla
He, Cixin S.
Okpara, Chinyere E.
McKenzie, Jodi
Choueiri, Toni K.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
[38] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
Hutson, Thomas E.
Michaelson, M. Dror
Kuzel, Timothy M.
Agarwal, Neeraj
Molina, Ana M.
Hsieh, James J.
Vaishampayan, Ulka N.
Xie, Ran
Bapat, Urmi
Ye, Weifei
Jain, Rohit K.
Fishman, Mayer N.
EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
[39] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
不详
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
[40] A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
Tannir, Nizar M.
Plimack, Elizabeth
Chaan Ng
Tamboli, Pheroze
Bekele, Nebiyou B.
Xiao, Lianchun
Smith, Lisa
Lim, Zita
Pagliaro, Lance
Araujo, John
Aparicio, Ana
Matin, Surena
Wood, Christopher G.
Jonasch, Eric
EUROPEAN UROLOGY, 2012, 62 (06) : 1013 - 1019

← 1 2 3 4 5 →